HOTLINE: Effective November 23, 2020

New Test Available Now | **3003443** | **Influenza, SARS-CoV-2, and RSV by NAA** | **FLUCOVRSV**

Patient Demographics Form for Public Health Reporting

Specimen Collection and Handling

Additional Technical Information

Methodology: Qualitative Nucleic Acid Amplification
Performed: Daily
Reported: 1-4 days

Specimen Required: Collect: Nasopharyngeal swab.
Also acceptable: Oropharyngeal swab, nasal swab.
Refer to the "COVID-19 Specimen Collection Guide" at https://www.aruplab.com/infectious-disease/coronavirus/testing
Specimen Preparation: **Nasopharyngeal swab:** Place in viral transport media (ARUP supply #12884) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787, Liquid Amies, or saline (minimum volume 1.2mL). Place each specimen in an individually sealed bag.
Oropharyngeal or nasal swab: Place in viral transport media (ARUP supply #12884) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787, Liquid Amies, or saline (minimum volume 1.2mL). Place each specimen in an individually sealed bag.
Storage/Transport Temperature: Frozen
Remarks: Specimen source required.
Unacceptable Conditions: Swabs not in media. Wood swabs, calcium alginate swabs. Media with guanidine-containing materials, 'molecular media' that indicates inactivation of pathogens and preservation of RNA/DNA, charcoal media. Specimens sent in tubes with pop-top lids/caps. Specimens in glass tubes.
Stability (collection to initiation of testing): **Swabs:** Ambient: Unacceptable; Refrigerated: 2 days; Frozen: 1 month

Interpretive Data:
This test is intended for the qualitative detection and differentiation of 2019 novel coronavirus SARS-CoV-2, influenza A/B virus, and/or RSV virus RNA from individuals suspected of respiratory viral infection.

Not Detected results do not rule out the presence of PCR inhibitors in the patient specimen or assay-specific nucleic acid in concentrations below the level of detection by the assay.

Detected results are indicative of the presence of SARS-CoV-2, influenza A/B, or RSV virus RNA. Due to the complexity of nucleic acid amplification methodologies, there may be a risk of false-positive results. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.

Reliable results are dependent on adequate specimen collection, transport, storage, and handling.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: This test detects and differentiates RNA from 2019 novel coronavirus SARS-CoV-2, influenza A/B virus, and RSV virus. This test does NOT differentiate between influenza A or B.

CPT Code(s): 87637

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.